EPCAM and cancer: This Food and Drug Administration (FDA)-approved first-generation instrumentation relied on a single CSM epithelial cell adhesion molecule (EpCAM) to capture CTCs, followed by CTC enumeration to provide cancer prediction, prognosis, and clinical outcomes [74,75,76,77,78].